VACCINE EFFECTIVENESS AGAINST INFECTIONS TRIGGERING AUTOIMMUNE DISEASE
Dr Deborah Burnett,
Scientia Senior Lecturer & Laboratory Head
UNSW Sydney, Australia
RESEARCHER PROFILE
Filmed in Sydney, Australia | April 2026
Dr Deborah Burnett is a Scientia Senior Lecturer and Laboratory Head at UNSW, where she leads a multidisciplinary research program spanning mechanistic immunology and translational vaccinology. Her work focuses on understanding how immune responses can protect against challenging infectious threats, including bacterial infections and infections associated with autoimmune disease.
After completing her PhD in 2019, Dr Burnett established her first independent group at the Garvan Institute in 2022 and launched her laboratory at UNSW in 2024. Her research, published in major research journals including Science and Immunity, has helped redefine how self-reactive B cells contribute to protective immunity and is now shaping new approaches to prevention and cure of infections linked to autoimmunity.
Her contributions to research leadership and translation have been recognised through the NSW Premier’s Prize for Early Career Researcher of the Year, Research Australia’s Discovery Award, the Australian L’Oréal-UNESCO For Women in Science Fellowship, a Young Tall Poppy Award, the Marie Krogh Prize for Women in Science, and selection as an International Union of Immunological Societies Rising Star. Through the Snow Fellowship, Dr Burnett and her team aim to develop new ways to distinguish protective from harmful immune responses, advancing safer vaccines, diagnostics and therapies for vulnerable communities affected by infection-associated autoimmune disease.
Source: Supplied
https://orcid.org/0000-0002-5642-3315
-
Novel therapy for pancreatic cancers, targeting molecular foundation
Dr Michael Lee is an experienced medical oncologist, sub-specialising in gastrointestinal cancers and neuroendocrine tumours at the Peter MacCallum Cancer Centre.
He plays a key role in molecular tumour boards at VCCC Alliance (Victorian Comprehensive Cancer Centre) and MPCCC (Monash Partners Comprehensive Cancer Consortium), ensuring the accurate and effective use of precision medicine in cancer care across the state.
-
Impact of NextSense Institute Research in the field of sensory disabilities
NextSense has a 165 year history of providing services and education for individuals with sensory impairments. With the support of donations, NextSense provides vital support for children and adults, more cochlear implants than any other service in Australia, and is a world leader for research, technology and professional education in the fields of visions and hearing loss.
NextSense clinicians are actively involved in a number of leading research projects—both independently and in collaboration with local and international organisations. The NextSense Institute, part of NextSense is Australia’s leading centre for research and professional education in the field of sensory disabilities.
-
Patient reported outcomes in the diagnosis and treatment of lymphoma
Dr. Elizabeth Goodall (BMedSci Hons, MBBS Hons, FRACP, FRCPA) is a PhD student and early career researcher with La Trobe University and the Olivia Newton John Cancer Research Institute (ONJCRI), and Haematologist at Austin Health and Monash Health, Melbourne.
Her specific interest in how patients experience their illness and treatment forms the basis for her research in improving patient outcomes. This research comes at a pivotal time in modern lymphoma management with an ever-increasing number of treatment options available and renewed focus on each patient’s journey.
